García-Vicuña, Rosario https://orcid.org/0000-0001-9096-3780
Garrido, Noemí
Gómez, Susana https://orcid.org/0000-0002-5337-2970
Joven, Beatriz https://orcid.org/0000-0003-1140-7618
Queiro, Rubén https://orcid.org/0000-0002-8418-7145
Ramírez, Julio https://orcid.org/0000-0002-7047-8056
Rebollo, Francisco https://orcid.org/0000-0003-3651-3687
Loza, Estíbaliz https://orcid.org/0000-0002-4607-9178
Sellas, Agustí https://orcid.org/0000-0003-2812-2467
Funding for this research was provided by:
Pfizer Spain
Article History
Received: 9 March 2021
Accepted: 23 April 2021
First Online: 2 May 2021
Declarations
:
: All of the authors received honoraria from Pfizer for participation in this project. Francisco Rebollo and Susana Gómez work for Pfizer. Agustí Sellas has received honoraria as speaker and for consulting from Pfizer, Lilly Novartis, Janssen, Amgen. Julio Ramírez has participated at symposiums and/or advisory boards organised by Pfizer, Abbvie, MSD, UCB, Novartis, BMS, Lilly, Janssen, Amgen and Roche and his department has received research grants from Pfizer, Abbvie, Novartis and Janssen. Rubén Queiro has received honoraria as speaker, researcher and consultor from Janssen, Lilly, MSD, Abbvie, Pfizer, UCB, Celgene-Amgen, Novartis. Rosario García-Vicuña reports personal fees from Pfizer, during the conduct of the study; grants, personal fees and non-financial support from Abbvie, grants, personal fees and non-financial support from BMS, personal fees from Biogen, personal fees from Celltrion, grants, personal fees and non-financial support from Lilly, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from MSD, personal fees and non-financial support from Pfizer, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants from Janssen, outside the submitted work. Estibaliz Loza has received research grants from Janssen, Lilly, MSD, Abbvie, Pfizer, UCB, Celgene-Amgen, Roche, Abbvie, BMS, Novartis. Noemí Garrido has received personal fees from Pfizer, Abbie, Lilly, Gedeon Richter, Novartis, Sanofi y Janssen. The rest of authors declare no conflicts of interest.